Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11371-11380
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11371
Figure 1
Figure 1 Flow chart of the study. HCC: Hepatocellular carcinoma; ETV: Entecavir; BMI: Body mass index.
Figure 2
Figure 2 Dynamic changes in estimated glomerular filtration rate, CHOL, triglycerides during 3-year tenofovir disoproxil fumarate treatment. A: Dynamic changes of estimated glomerular filtration rate (eGFR), cholesterol (CHOL), triglycerides (TG) in total population; B: Dynamic changes of eGFR, CHOL, TG in non-overweight population; C: Dynamic changes of eGFR, CHOL, TG in overweight population. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; CHOL: Cholesterol; TG: Triglycerides.
Figure 3
Figure 3 Correlation analysis between estimated glomerular filtration rate and lipid profiles. A: Correlation between estimated glomerular filtration rate (eGFR) and triglycerides (TG) in non-overweight population; B: Correlation between eGFR and cholesterol (CHOL) in non-overweight population; C: Correlation between eGFR and TG in overweight population; D: Correlation between eGFR and CHOL in overweight population. BMI: Body mass index; TDF: Tenofovir disoproxil fumarate; eGFR: Estimated glomerular filtration rate; TG: Triglycerides; CHOL: Cholesterol.